Why McKesson (MCK) is a Top Value Stock for the Long-Term

Zacks highlights McKesson as a potential long-term value stock, citing a VGM score of A, Value score of B and forward P/E of 22.36; its Zacks Rank is #3 (Hold). FY2027 consensus EPS rose $0.06 to $44.71 after one analyst revised estimates upward in the past 60 days, while McKesson’s average earnings surprise is +4.3%. The article also identifies specialty pharmaceuticals, oncology services and GLP-1 drugs as growth drivers, with GLP-1 revenue nearing $41 billion in FY2025.

Analysis

The promotional “value” case is weaker than its headline: a #3 (Hold) ranking and a $0.06 consensus EPS increase, reportedly driven by one analyst revision, do not establish broadening earnings momentum. The key economic distinction is revenue versus value capture. The cited GLP-1 sales base may support distribution volumes, but high pass-through sales need not translate into comparable gross profit or cash generation; working-capital demands and manufacturer pricing or channel changes could absorb part of the benefit. Track segment gross profit and operating cash conversion, not headline sales growth.

Over 1–3 months, the catalyst is estimate breadth and guidance, rather than the style-score label. If revisions spread and cash conversion holds, the market may reward the higher-quality specialty and oncology mix. Over 6–18 months, GLP-1 channel economics, customer concentration, and purchasing leverage matter more than current revenue momentum. A supply normalization, reimbursement pressure, or greater direct distribution could reduce volume or economics. McKesson also competes with Cardinal Health and Cencora; any sector-wide pricing or contract pressure could limit company-specific upside.

Contrarian read: the article’s valuation framing may understate execution and cash-flow risk, while the strong revenue narrative may overstate earnings sensitivity. The supplied forward multiple is not enough to call the shares cheap without peer, cash-flow, and segment-profit context. No immediate directional trade is justified on this evidence alone.

Key Decisions for Investors

• Do not chase MCK on the article’s style scores. Treat the modest estimate revision and Hold rank as a weak signal until subsequent updates show broader analyst participation.
• Set an earnings-monitoring alert for segment gross profit, operating cash conversion, working-capital requirements, and guidance on specialty/GLP-1 economics. Strong sales with deteriorating cash conversion would falsify the quality-growth thesis.
• Revisit a long MCK or relative-value position against Cardinal Health and Cencora only after comparing current valuation, segment profitability, and estimate-revision breadth; those inputs are absent here.
• Watch for evidence of GLP-1 distribution shifts, supply normalization, reimbursement changes, or customer purchasing pressure. These are the principal 6–18 month downside risks to the implied growth narrative.